GLENMARK LIFE SCIENCES share price has plunged 6% and is presently trading at Rs 1,201.0.
Meanwhile, the BSE HEALTHCARE index is at 43,502.8 (down 0.6%).
Among the top losers in the BSE HEALTHCARE index today are FDC (down 5.0%) and ALEMBIC PHARMA (down 4.2%).
SUVEN PHARMACEUTICALS (up 4.1%) and AJANTA PHARMA (up 1.8%) are among the top gainers today.
Over the last one year, GLENMARK LIFE SCIENCES has moved up from Rs 646.2 to Rs 1,201.0, registering a gain of Rs 554.9 (up 85.9%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,508.7 to 43,502.8, registering a gain of 52.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 164.2%), SUVEN PHARMACEUTICALS (up 115.1%) and Glenmark Pharma (up 91.7%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 83,190.5 (up 0.3%).
The top gainers among the BSE Sensex today are NTPC (up 2.8%) and Nestle (up 2.1%). The most traded stocks in the BSE Sensex are NTPC and Tata Steel.
In the meantime, NSE Nifty is at 25,411.4 (up 0.1%). NTPC and Nestle are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 67,596.8 to 83,190.5, registering a gain of 15,593.6 points (up 23.1%).
GLENMARK LIFE SCIENCES net profit fell 17.7% YoY to Rs 1,115 million for the quarter ended June 2024, compared to a profit of Rs 1,355 million a year ago. Net sales rose 1.8% to Rs 5,886 million during the period as against Rs 5,785 million in April-June 2023.
For the year ended March 2024, GLENMARK LIFE SCIENCES reported 0.8% increase in net profit to Rs 4,709 million compared to net profit of Rs 4,670 million during FY23. Revenue of the company grew 5.6% to Rs 22,832 million during FY24.
The current Price to earnings ratio of GLENMARK LIFE SCIENCES, based on rolling 12 month earnings, stands at 32.9.
Equitymaster requests your view! Post a comment on "GLENMARK LIFE SCIENCES Plunges 6%; BSE HEALTHCARE Index Down 0.6%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!